Curaleaf Pens Letter To Aurora Cannabis Shareholders Urging Acceptance Of Its Takeover Offer

Aurora Cannabis Re-Affirms FY27 Q2 Guidance For Sequential Growth In Quarterly Net Revenue And Adjusted EBITDA

Re-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA1Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

Aurora Cannabis Says Curaleaf Application To Halt Its ATM Program Is Attempt To Distract From Inadequate Hostile Bid, Says ATM Was Disclosed In February 2026 Before Offer; Board Reiterates Unanimous Recommendation To Reject Bid

8-K filing — Curaleaf Holdings, Inc. (CURLF)

Filed: 2026-09-16 AccNo: 0001756770-26-000111 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Aurora Cannabis Fires Back at Curaleaf’s Hostile Takeover Bid

Aurora Cannabis urges shareholders to reject Curaleaf's unsolicited hostile bid, calling the offer undervaluation with serious risks.